Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Liabilities: 2015-2025

Historic Total Liabilities for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $176.9 million.

  • Intellia Therapeutics' Total Liabilities fell 16.08% to $176.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.9 million, marking a year-over-year decrease of 16.08%. This contributed to the annual value of $319.1 million for FY2024, which is 27.21% up from last year.
  • Intellia Therapeutics' Total Liabilities amounted to $176.9 million in Q3 2025, which was down 3.70% from $183.6 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Total Liabilities registered a high of $319.1 million during Q4 2024, and its lowest value of $171.0 million during Q1 2021.
  • Its 3-year average for Total Liabilities is $222.1 million, with a median of $218.4 million in 2023.
  • As far as peak fluctuations go, Intellia Therapeutics' Total Liabilities spiked by 155.28% in 2021, and later fell by 20.64% in 2023.
  • Over the past 5 years, Intellia Therapeutics' Total Liabilities (Quarterly) stood at $254.2 million in 2021, then increased by 11.92% to $284.5 million in 2022, then fell by 11.85% to $250.8 million in 2023, then increased by 27.21% to $319.1 million in 2024, then declined by 16.08% to $176.9 million in 2025.
  • Its Total Liabilities was $176.9 million in Q3 2025, compared to $183.6 million in Q2 2025 and $206.2 million in Q1 2025.